ACCURAY INCORPORATED Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2026-08-25: Study NCT07691255; Company role Collaborator; Phase Observational; Status Recruiting.
- 2025-05-02: Study NCT06360653; Company role Collaborator; Phase Not applicable; Status Recruiting.
- 2018-05-08: Study NCT03377517; Company role Collaborator; Phase Not applicable; Status Terminated.
- 2016-06-23: Study NCT02716948; Company role Collaborator; Phase Phase 1; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2026-08-25 | NCT07691255 MELanoma Brain Metastasis Treated With CYberknife | Collaborator Lead: European Institute of Oncology | Observational | Recruiting | Melanoma (Skin Cancer) | 50 | 2030-01-01 |
| 2025-05-02 | NCT06360653 a SIngle Center Study of Post-operative STEReotactic RAdiotherapY for Endometrial Cancer | Collaborator Lead: ARNAS Civico Di Cristina Benfratelli Hospital | Not applicable | Recruiting | Endometrial Cancer | 60 | 2027-05 |
| 2018-05-08 | NCT03377517 Radiosurgical Hypophysectomy for Bone Metasteses Pain | Collaborator Lead: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Not applicable | Terminated Results posted | Bone Metastases | 5 | 2024-05-15 |
| 2016-06-23 | NCT02716948 SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine | Collaborator Lead: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 | Completed | Metastatic Malignant Neoplasm in the Brain; Metastatic Malignant Neoplasm in the Spine; Stage IV Skin Melanoma | 17 | 2021-08-27 |
| 2015-12 | NCT02701088 Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life | Collaborator Lead: Centre Francois Baclesse | Phase 2 | Completed Results posted | Locally Advanced Anal Canal Cancer | 71 | 2025-12-31 |
| 2011-02 | NCT01327521 Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma | Collaborator Lead: Albert Koong | Phase 3 | Withdrawn | Carcinoma, Hepatocellular | 0 | |
| 2011-02 | NCT01318200 Transarterial Chemoembolization (TACE) vs. CyberKnife for Recurrent Hepatocellular Carcinoma (HCC) | Lead sponsor | Phase 3 | Withdrawn | Recurrent Hepatocellular Carcinoma | 0 | 2016-02 |
| 2011-01 | NCT01318447 CyberKnife® for Hepatic Metastases From Colorectal Cancer | Lead sponsor | Phase 2 | Terminated | Colorectal Liver Metastases | 15 | 2013-03 |
| 2008-12 | NCT00840749 Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer | Lead sponsor | Not applicable | Terminated Results posted | Non-small Cell Lung Cancer | 36 | 2013-03 |
| 2007-12 | NCT00643994 CyberKnife Radiosurgery for Organ-Confined Prostate Cancer: Homogenous Dose Distribution | Lead sponsor | Not applicable | Completed Results posted | Prostate Cancer; Prostatic Cancer; Prostate Neoplasms; Prostatic Neoplasms; Cancer of the Prostate | 379 | 2021-01-27 |
| 2007-10-22 | NCT00643617 CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry | Lead sponsor | Not applicable | Completed Results posted | Prostate Cancer; Prostatic Cancer; Prostatic Neoplasms; Prostate Neoplasms; Cancer of the Prostate | 307 | 2022-04-07 |
| 2006-04 | NCT00643318 CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer | Lead sponsor | Phase 2 | Unknown | Non-small Cell Lung Cancer | 40 | 2021-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Glucotrack, Inc. (GCTK) | United States | $0.027B | |
| PAVmed Inc. (PAVM) | United States | $0.031B | -3.00 |
| HeartBeam, Inc. (BEAT) | United States | $0.022B | -2.08 |
| InspireMD, Inc. (NSPR) | $0.033B | ||
| RETRACTABLE TECHNOLOGIES INC (RVP) | United States | $0.021B | -6.44 |
| FEMASYS INC (FEMY) | United States | $0.020B | -1.07 |
| Modular Medical, Inc. (MODD) | United States | $0.018B | -0.88 |
| SeaStar Medical Holding Corp (ICU) | United States | $0.015B | -1.14 |
| CERENOME, INC. (CNSY) | United States | $0.014B | |
| Sintx Technologies, Inc. (SINT) | United States | $0.012B | -1.10 |